Advertisement

Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial

      Abstract

      Background

      Reactive oxygen species activate EGFR/RAS/MAPK signaling either through the inactivation of phosphatases or by direct oxidation of kinases. We hypothesized that functional single-nucleotide polymorphisms (SNPs) in antioxidant genes link to the efficacy of cetuximab in patients with metastatic colorectal cancer (mCRC).

      Patients and Methods

      We analyzed genomic and clinical data from FIRE-3, a phase III trial comparing cetuximab and bevacizumab along with FOLFIRI in untreated mCRC patients. Genomic DNA extracted from blood samples was genotyped. Thirteen functional SNPs in antioxidant genes were tested for associations with clinical outcomes.

      Results

      In total, 236 patients were included (FOLFIRI/cetuximab arm, n = 129; FOLFIRI/bevacizumab arm, n = 107). In univariate analysis, two SNPs (TXN2 rs4821494 and GPX4 rs4807542) were significantly associated with overall survival (OS) in the FOLFIRI/cetuximab arm. Multivariate analysis confirmed the significant association of TXN2 rs4821494 (T/T vs. any G allele, hazard ratio = 2.47, 95% confidence interval = 1.06–5.72, P = .03). In the FOLFIRI/bevacizumab arm, no SNPs were significantly associated with clinical outcomes. Treatment-by-SNP interaction test confirmed the predictive value of TXN2 rs4821494 (OS: P = .03).

      Conclusion

      TXN2 rs4821494 involved in the antioxidant system may predict the efficacy of cetuximab-based first-line chemotherapy in mCRC, warranting further validation studies.

      Keywords

      Abbreviations:

      CI (confidence interval), GTEx (Genotype-Tissue Expression), HR (hazard ratio), mCRC (metastatic colorectal cancer), ORR (overall response rate), OS (overall survival), PFS (progression-free survival), ROS (reactive oxygen species), SNP (single-nucleotide polymorphism)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Holmstrom KM
        • Finkel T.
        Cellular mechanisms and physiological consequences of redox-dependent signalling. Nature reviews.
        Mol Cell Biol. 2014; 15: 411-421
        • Hayes JD
        • Dinkova-Kostova AT
        • Tew KD.
        oxidative stress in cancer.
        Cancer cell. 2020; 38: 167-197
        • Dewhirst MW
        • Cao Y.
        Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.
        Nat Rev Cancer. 2008; 8: 425-437
        • Kirtonia A
        • Sethi G
        • Garg M.
        The multifaceted role of reactive oxygen species in tumorigenesis.
        Cell Mol Life Sci. 2020; 77: 4459-4483
        • Hussain SP
        • Harris CC.
        Inflammation and cancer: an ancient link with novel potentials.
        Int J Cancer. 2007; 121: 2373-2380
        • Kohan R
        • Collin A
        • Guizzardi S
        • Tolosa de Talamoni N
        • Picotto G
        Reactive oxygen species in cancer: a paradox between pro- and anti-tumour activities.
        Cancer Chemother Pharmacol. 2020; 86: 1-13
        • Laurent A
        • Nicco C
        • Chereau C
        • et al.
        Controlling tumor growth by modulating endogenous production of reactive oxygen species.
        Cancer Res. 2005; 65: 948-956
        • Chun KS
        • Kim DH
        • Surh YJ.
        Role of reductive versus oxidative stress in tumor progression and anticancer drug resistance.
        Cells. 2021; 10
        • Paulsen CE
        • Truong TH
        • Garcia FJ
        • et al.
        Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity.
        Nat Chem Biol. 2011; 8: 57-64
        • Heo J
        • Campbell SL.
        Superoxide anion radical modulates the activity of Ras and Ras-related GTPases by a radical-based mechanism similar to that of nitric oxide.
        J Biol Chem. 2005; 280: 12438-12445
        • Monteiro HP
        • Arai RJ
        • Travassos LR.
        Protein tyrosine phosphorylation and protein tyrosine nitration in redox signaling.
        Antioxidants & redox signaling. 2008; 10: 843-889
        • Mitsushita J
        • Lambeth JD
        • Kamata T.
        The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation.
        Cancer Res. 2004; 64: 3580-3585
        • Ferro E
        • Goitre L
        • Baldini E
        • Retta SF
        • Trabalzini L.
        Ras GTPases are both regulators and effectors of redox agents.
        Methods Mol Biol. 2014; 1120: 55-74
        • Heinemann V
        • von Weikersthal LF
        • Decker T
        • et al.
        FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
        Lancet. Oncol. 2014; 15: 1065-1075
        • Heinemann V
        • Stintzing S
        • Modest DP
        • Giessen-Jung C
        • Michl M
        • Mansmann UR
        Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
        Eur J Cancer. 2015; 51: 1927-1936
        • Lu J
        • Holmgren A.
        The thioredoxin superfamily in oxidative protein folding.
        Antioxidants & redox signaling. 2014; 21: 457-470
        • Jia JJ
        • Geng WS
        • Wang ZQ
        • Chen L
        • Zeng XS.
        The role of thioredoxin system in cancer: strategy for cancer therapy.
        Cancer Chemother Pharmacol. 2019; 84: 453-470
        • Leone A
        • Roca MS
        • Ciardiello C
        • Costantini S
        • Budillon A.
        Oxidative stress gene expression profile correlates with cancer patient poor prognosis: identification of crucial pathways might select novel therapeutic approaches.
        Oxid Med Cell Longev. 2017; 20172597581
        • Rabik CA
        • Dolan ME.
        Molecular mechanisms of resistance and toxicity associated with platinating agents.
        Cancer Treat Rev. 2007; 33: 9-23
        • Sun Y
        • Rigas B.
        The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents.
        Cancer Res. 2008; 68: 8269-8277
        • Sobhakumari A
        • Love-Homan L
        • Fletcher EV
        • et al.
        Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism.
        PloS one. 2012; 7: e48175